Cross-Reactive Immunity Among Flaviviruses

Abhay P. S. Rathore** and Ashley L. St. John†,‡,§,∥

1 Department of Pathology, Duke University Medical Center, Durham, NC, United States, 2 Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, Singapore, 3 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 4 SingHealth Duke-National University of Singapore Global Health Institute, Singapore, Singapore

Flaviviruses consist of significant human pathogens responsible for hundreds of millions of infections each year. Their antigenic relationships generate immune responses that are cross-reactive to multiple flaviviruses and their widespread and overlapping geographical distributions, coupled with increases in vaccination coverage, increase the likelihood of exposure to multiple flaviviruses. Depending on the antigenic properties of the viruses to which a person is exposed, flavivirus cross-reactivity can be beneficial or could promote immune pathologies. In this review we describe our knowledge of the functional immune outcomes that arise from varied flaviviral immune statuses. The cross-reactive antibody and T cell immune responses that are protective versus pathological are also addressed.

Keywords: flavivirus, dengue, Zika, yellow fever, tick-borne encephalitis, cross-protection, vector-borne

INTRODUCTION TO FLAVIVIRUSES

Flaviviruses are enveloped single-stranded positive-sense RNA viruses that share conserved structural and genomic features (1). The viral genome encodes for three structural and seven non-structural proteins that are needed for virus replication and assembly (1). Some of the most prominent mosquito-borne flaviviral human pathogens include the hemorrhagic fever viruses, dengue (DENV) and yellow fever (YFV), and neurotropic viruses, such as West Nile (WNV), Japanese encephalitis (JEV), Saint Louis encephalitis (SLEV), and Zika (ZIKV). Yet other flaviviruses that are human pathogens, such as Kyasanur forest disease (hemorrhagic) and Powassan (encephalitic) viruses, are tick-borne. Additional flaviviruses have no known vector (2) while others are thought to be restricted to insects or bats and are not reported to cause human disease (3). Phylogenetic analysis has shown that flaviviruses cluster in genomic similarity according to their dominant vector (Figure 1), which also is a major contributing factor to the often-overlapping global distribution patterns of each flavivirus. The genetic differences amongst flaviviruses result in both conserved and species-specific attributes, such as cellular and tissue tropism upon infection and, importantly for the purposes of this review, antigenic properties.

CLASSIFICATION AND ANTIGENIC RELATIONSHIPS AMONG FLAVIVIRUSES

The name flavivirus (flavus- means “yellow” in Latin) stems from early research done on the YFV vaccine in 1930s, for which a Nobel Prize was awarded to Marx Theiler in 1951 (4). In the initial classification scheme, arthropod-borne viruses were classified based on their ability to replicate and...
transmit through arthropods and distributed in to two groups belonging to the family Togaviridae (5). Group A comprised of arthropod-borne viruses such as chikungunya and sindbis (now in the genus alphavirus) and Group B comprised of viruses such as YFV and DENV (now in the genus flavivirus, and the subjects of this review). Because of the distinct antigenic characteristics of flaviviruses, they were later classified in to the new genus, flavivirus of the family Flaviviridae (6). The first arthropod-borne virus cross-reactivity was observed in complement fixation tests (7), which allows a complement reaction to occur on the surface of red blood cells (RBCs) when serum is added in the presence of a known antigen. Later, the hemagglutination inhibition assay, involving inhibition of virus-induced hemagglutination (or aggregation of RBCs) in the presence of serum was used to describe flavivirus cross-reactivity (8). Further, serological studies utilizing virus-neutralizing tests have strengthened the concept of flavivirus cross-reactivity and segregated flaviviruses that are mosquito-borne, tick-borne, and those with no known arthropod vectors (5, 9). The antigenic similarities between flaviviruses are a secondary attribute that emerges owing to their genetic similarities. As a result, infection with one flavivirus results in both species-specific and flavivirus cross-reactive antibodies. The majority of flaviviruses that are relevant to human disease were organized into 8 serocomplexes...
plus 17 independent viruses that were not antigenically similar enough to warrant inclusion in a serocomplex (9) (Figure 1). Serocomplexes were defined by the ability of polyclonal post-immune sera against one flavivirus to neutralize others (10). Using DENV as an example, there are 4 serotypes of DENV (DENV1-4), which induce antibodies that are able to cross-neutralize each other to a certain degree, especially at high concentrations, in spite of those antibodies being insufficient to provide efficient neutralization and protection from secondary heterologous infections in vivo (10). In contrast, DENV-immune sera were unable to neutralize ZIKV, even though the serology indicated a relationship by another serological method [e.g. Enzyme-linked immunosorbent assay (ELISA)], supporting its close relationship to DENV but indicating that it falls into an independent serocomplex (11, 12). First described using human sera, these flavivirus cross-reactive immune responses appear to be consistent for multiple mammalian species, including rodents and non-human primates (13–15). During the acute phase of infection and disease, flavivirus cross-neutralizing antibodies can be induced, but these are usually not durable and cross-neutralization is not retained following a few months (12). Those exposed to multiple flaviviruses may also generate responses more difficult to decipher and which cross-neutralize viruses from distantly related serocomplexes (16, 17).

With the global spread of flavivirus vectors, increased human mobility, and increased vaccine coverage against flaviviruses, we are not only concerned with how pre-existing immunity could affect a heterologous challenge with a new virus from the same serocomplex (e.g. DENV2 infection followed by DENV1 infection) but also how immunity is influenced by sequential exposure to multiple flaviviruses from differing serocomplexes. Notwithstanding the potential of anti-flavivirus memory immune responses to influence subsequent infections, the high degree of immune cross-reactivity to flaviviruses makes infections, and prior exposures difficult to definitively identify when virologic confirmation is not possible (18).

**FUNCTIONAL IMMUNE OUTCOMES OF SEQUENTIAL FLAVIVIRUS INFECTIONS**

As humans have become more likely to experience more than one flavivirus infection during a lifetime, there is a need to understand how pre-existing immunity to a flavivirus impacts subsequent flavivirus infection outcomes. Early studies in humans exploring the nature of immune protection against flaviviruses observed that functional immune responses (virus neutralization) and the course of infection were modulated in the context of pre-existing flavivirus cross-reactive immunity (19, 20). While human studies have been largely correlation-based, studies using animal models have provided more definitive functional disease outcomes. For example, immunity to JEV and SLEV was protective against lethal WNV challenge in a hamster model (15). Similar cross-protection was observed when mice were immunized with Usutu virus and challenged with WNV (21). Within the same serocomplex, prior exposure to Kunjin or Murray Valley encephalitis (MVEV) viruses in pigs was also protective against JEV challenge (22). These studies suggest that cross-reactive immunity may be protective within the JEV serocomplex. In contrast, in a human DENV challenge study, immunity to DENV only provided lasting protection against a homologous DENV serotype (10, 19). Within the YFV complex, primary infection of rhesus macaques with Wesselsbron virus (from the YFV serocomplex) was protective against YFV challenge (13) and, more recently, examining the possibility of cross-protection against viruses in differing serocomplexes, JEV vaccination was shown to provide cross-protection against DENV and to increase the kinetics of the development of neutralizing antibody responses (14). Certain DENV or ZIKV-specific human monoclonal antibodies also can protect against a Spondweni virus challenge in immune compromised mice (23). However, primary infection with WNV (from the JEV serocomplex) or Banzi virus (from the YFV complex) failed to provide any protection against YFV challenge (13). The differences between cross-protection versus pathology have been more controversial in the context of how pre-existing immunity to DENV influences subsequent ZIKV infection. While some studies in immune compromised mice have suggested that DENV T cell immunity can be protective against ZIKV infection in adult mice (24), other studies in STAT2-KO mice, with impaired immunity, showed prior DENV immunity can enhance infection in adult mice and infection and fetal demise in pregnant mice (25, 26). In immune competent mice, pre-existing DENV immunity can enhance the development of a microcephaly phenotype in fetuses (27, 28), which is a key characteristic pathology of disease. These studies suggest that various factors determine cross-protection, some of which are discussed below.

**FLAVIVIRUS CROSS-REACTIVE T CELL RESPONSES**

Various subsets of T cells are essential for efficient infection clearance and for the development of robust antibody responses against flaviviruses. Flavivirus reactive T cell epitopes have been identified in both viral structural and non-structural proteins and for CD8 and CD4 T cells (14, 29). Often, we expect that the T cell epitope must be 100% conserved to induce recall of a memory T cell from a previous infection; however, similar epitopes with only minor substitutions often are able to activate T cells as well although with potentially differing degrees of responses (30, 31). Early studies using murine T lymphocyte clones demonstrated T cell cross-reactivity similar to that observed using antibody neutralization tests (32, 33). For example, T cell clones specific to Kunjin or WNV showed cross-reactivity with MVEV or vice versa (32), suggesting T cell cross-reactivity within the JEV serocomplex. T cell cross-reactivity between two different serocomplexes has also been observed. CTL clones specific for DENV reacted and proliferated against Kunjin (JEV’serocomplex), a virus from different serocomplex than DENV (34). Similarly, DENV or ZIKV induced CD8
T cell responses are also noted to be highly cross-reactive against each other (35). While the majority of flavivirus cross-reactive CD8 T cells are directed against viral non-structural proteins, studies using chimeric viruses have identified cross-reactive CD8 T cell epitopes that are present in the viral envelope protein (36). This suggests that both conserved non-structural proteins and variable structural proteins contribute toward the development of the flavivirus cross-reactive CD8 T cell repertoire. Interestingly, for human T cells, prior exposure to DENV skewed the immunodominance of ZIKV-specific T cells toward non-structural proteins (35), yet these cross-activated T cells retained their ex vivo functionality (37). This cross-reactivity may be beneficial for clearing a secondary infection since it has been shown that a vaccine utilizing non-structural epitopes of DENV can protect against DENV infection in mice (38). Still, the broad question of whether flavivirus cross-reactive CD8 T cells are protective or pathological in nature remains to be resolved. Indeed, within the DENV serocomplex, certain cross-reactive CD8 T cell epitopes have been associated with severe disease in humans (39, 40), illustrating the potential of cross-reactive CD8 T cells that have a T effector memory phenotype may be beneficial for clearing a secondary infection since it has been shown that a vaccine utilizing non-structural epitopes of DENV can protect against DENV infection in mice (38). Still, the broad question of whether flavivirus cross-reactive CD8 T cells are protective or pathological in nature remains to be resolved. Indeed, within the DENV serocomplex, certain cross-reactive CD8 T cell epitopes have been associated with severe disease in humans (39, 40), illustrating the potential of cross-reactivity to reduce the efficiency of an antigen-specific response (41, 42). More recently, the functional role of serocomplex cross-reactive CD4 T cells has been identified, where they were shown to be associated with improved viral clearance during secondary serocomplex heterologous infection (14). Genetic similarity appeared to be a factor in cross-protection in this context, where JEV provided better CD4-dependent cross-protection against DENV than the more distantly related YFV in the mouse model (14). Importantly, CD4 T follicular helper (Tfh) cells with an effector memory phenotype were shown to be critical for efficient memory recall and in improving the quality of antibody responses, providing a mechanism of cross-protection (14). In humans vaccinated against JEV, cross-reactive T effector memory cells were also identified, which could be activated to proliferate and produce interferon-gamma in response to antigens from all of the heterologous viruses tested including DENV, YFV, and ZIKV (14). During heterologous DENV infections, CD4 effector memory T cells that have a TEMRA phenotype, which is cytotoxic in nature, have also been identified (43, 44) and these may be present and recalled, in addition to cross-reactive Tfh cells, during heterologous flavivirus infection. It is probable that flavivirus cross-reactive CD4 TEMRA cells are also present in individuals exposed to varied flavivirus infections or vaccines but their frequency may be very low. However, the antigen presenting molecule, MHC-II is highly polymorphic in humans and therefore flavivirus CD4 T cell responses can be restricted to certain HLA-types making identified cross-reactive epitopes likely relevant for only those with the given HLA-types (10). Virion structure also determines cross-reactive CD4 T cell immunodominance, as certain structural protein conformations can provide immunodominant epitopes that are conserved structurally but not genetically among flaviviruses (45, 46).

### FLAVIVIRUS CROSS-REACTIVE ANTIBODY RESPONSES

The surface glycoprotein of a flavivirus consists of type-specific and serocomplex cross-reactive epitopes, owing to which the antibodies evoked are both type-specific and cross-reactive in nature (47–49). Structural determinants such as the conformation of epitopes and the presence of flavivirus conserved residues on the surface of the viral envelope (E) protein determine antibody binding and neutralization properties. For instance antigenic epitopes present on the surface of E protein, which consists of domains I, II, and III, are both linear and quaternary and immune activation to E generates antibodies that are largely neutralizing against the virus of same type (50–52). In the context of immune responses to E protein, antibodies that are neutralizing are better generated by the quaternary structures of E protein dimers, compared to the monomeric form of the protein (53). Moreover some E dimer epitopes are conserved across related flaviviruses and evoke antibodies that are cross-neutralizing to flaviviruses of differing serocomplexes, for example antibodies that can neutralize both DENV and ZIKV (54, 55). However, antibodies targeting the E protein fusion loop epitopes, which are conserved across various flaviviruses are also broadly cross-reactive but studies so far have indicated that they are poorly neutralizing (51). These weakly neutralizing cross-reactive antibodies may influence the course of subsequent flavivirus infection, as discussed below.

Both antibody specificity and concentration can govern the ability of antibodies to neutralize or enhance the uptake of virus by Fc-receptor bearing cells (56). In some cases, individual monoclonal antibodies that are capable of cross-neutralization may be identified from an otherwise sub-neutralizing pool (57). Conversely, weakly neutralizing antibodies often can lead to neutralization at high concentrations as was shown with WNV (58) which may factor in to the period of relative resistance to similar viral infections in the months immediately following infection (56). As a result of the decay of antibody in serum in the years following vaccination or natural infection, subsequent functional responses to new flaviviruses can be temporal (56).

There are antigenic relationships amongst flaviviruses that are rarely functionally tested in vivo in humans due to the infrequency of the two sequential infections. For example, antibody cross-reactivity to Yokose virus (from the Entebbe bat virus serocomplex) is also observed in patients’ sera infected or vaccinated with DENV or YFV (59). Yet, other sequential flavivirus challenges are much more common, such as the high probability of re-exposure to multiple serotypes of DENV or sequential exposures to DENV and ZIKV (60, 61). Much of our understanding of how flavivirus cross-reactive antibodies influence subsequent exposures to flaviviruses has been obtained in models of sequential DENV infections, where antibody-dependent enhancement of infection (ADE) by a heterologous serotype is consistently observed (10). This results from the binding of virus that is complexed with sub-neutralizing antibodies to the Fc receptors of immune cells including dendritic cells, monocyte/macrophages and mast cells (10). In this context, opsonization of virus can lead to enhanced infection in the
FIGURE 2 | Flavivirus cross-reactive cellular immune responses. Infection or vaccination against a flavivirus (Type-1) results in a primary immune response dominated by generation of Type-specific antibodies and T cell responses, followed by a memory formation. Owing to their antigenic relatedness, flavivirus cross-reactive antibodies and T cells (CD4 & CD8) are also generated. A secondary challenge with a second flavivirus (Type-2) can potentially reactivate cross-reactive memory T cells, those, which have higher specificity for Type-1 than for Type-2 flavivirus. These weakly cross-reactive memory T cells may outcompete naive T cells that would be more specific for Type-2, resulting in T cell original antigenic sin. However, memory T cells could also provide cross-protection directly by acquiring CTL function resulting in enhanced killing of virus-infected cells. Importantly cross-reactive CD4 Tfh cells can be recalled in the lymph node germinal centers, providing help to B cells, and improving both affinity and avidity of antibodies that are cross-reactive and neutralizing. Flavivirus cross-reactive antibodies also interact in different ways during a secondary flavivirus infection. After primary infection, high affinity and Type-specific antibodies are produced, which can neutralize virus when present at optimal concentrations. However, during secondary heterologous flavivirus infection, pre-existing cross-reactive, sub-neutralizing antibodies may lead to opsonization of virus particles and enhanced uptake by various immune cells such as monocytes via Fc receptors, resulting in increased virus replication, a phenomenon termed antibody-dependent enhancement (ADE).

immune cell types, resulting in both increased virus production and heightened production of pro-inflammatory mediators (10). Aside from opsonization, antibodies can also trigger alternate immune activation pathways such as Fc receptor cross-linking or antibody-dependent cellular cytotoxicity (ADCC) (10). During secondary heterologous exposures, mast cells activation is
observed downstream of IgG or IgE cross-linking upon virus binding (62, 63). NK cell mediated ADCC also can trigger release of pro-inflammatory and cytotoxic mediators (64). ADE occurs not only for DENV, but for other combinations of viruses from differing serocomplexes, such as DENV and ZIKV (65). Indeed, ADE of the attenuated YFV strain 17D was shown to occur in vivo in humans, depending on JEV vaccine-induced antibodies from a prior immunization (66). However, Fc receptor activation and binding by virus-immune complexes may not always be detrimental to the host. For example, prior vaccination to JEV was shown to enhance uptake of YFV vaccine (strain 17D) by antigen presenting cells in mouse lymph nodes, leading to increased immunogenicity of the attenuated YFV vaccine (66) and suggesting a potential utility to ADE when it improves adaptive immune responses.

Phylogenetic analyses suggest a close relationship between DENV and ZIKV (67) and studies testing human anti-DENV sera demonstrated a high degree of cross-reactivity (11). As discussed, despite this high cross-reactivity, DENV-specific antibodies fail to cross-neutralize ZIKV (12), but may lead to opsonization of ZIKV viral particles (65). Not only was this shown to occur in conventional antigen presenting cells, dependent on the Fc gamma receptors, DENV antibodies can also enhance uptake of ZIKV in the syncytiotrophoblasts, and fetal endothelial cells of the placenta in a mechanism dependent on the fetal neonatal Fc Receptor, FcRN (27). In support of the role of antibody dependent enhancement of ZIKV pathology in vivo in humans, mothers with antibodies that were highly enhancing to ZIKV were shown to have fetuses (or children) with more severe microcephaly phenotypes (68). This pathological influence of DENV immunity during subsequent ZIKV infection may be specific for the context of pregnancy, since epidemiologic studies in humans suggest that ZIKV infection rates may be reduced in DENV immune non-pregnant individuals (69).

Pre-existing immunity also has the potential to improve cross-reactive antibody responses that are developed during a heterologous flavivirus infection. When JEV immunity led to faster induction of neutralizing antibodies to DENV, adoptive transfer studies showed that it was based on recall of a heterologous memory response and increased germlinal center activity in lymph nodes, resulting in gains in antibody avidity and neutralization against DENV in JEV-exposed animals (14). However, there are also indications that the quality of antibodies can be impeded by prior flavivirus immunity. For example, in one study, individuals pre-vaccinated against YFV were shown to have a lower ratios of neutralizing to ELISA antibody titers (70), emphasizing that the quality of immune responses and not only the magnitude are important in determining the potential of cross-reactive immunity to induce protection versus pathology (Figure 2).

IMPLICATIONS FOR RATIONAL FLAVIVIRUS VACCINE DESIGN

Herd immunity needs to be maintained to keep the population protected from certain flaviviruses for which vaccines are available. YFV is an example of this need since outbreaks of YFV in South America and Africa have occurred in recent years coinciding with reductions in vaccine coverage (71, 72). The success of the YFV vaccine has largely been attributed to its safety and effectiveness as an attenuated vaccine that induces immune activation of multiple pathways including innate responses, and effective T cell and antibody responses (73). A vaccine does not need to provide 100% of individual's life-long durable protection to be effective, but the YFV vaccine often does. For this reason, it has been used as the “backbone” for other vaccines including the Sanofi Pasteur DENV vaccine, Dengvaxia (74). This means that the non-structural proteins of the 17D YFV vaccine were used to construct chimeric viruses with the structural proteins of each of the DENV1-4 viruses (74). Aside from its validated safety, the YFV backbone was also chosen for this DENV vaccination strategy because the replication rates could be closely matched for all serotypes, promoting similar antigen persistence in vivo (74). This was to counteract the problem that was discovered early on in DENV vaccine design, where one or two of the 4 serotypes replicated much more efficiently in vivo, leading to immune dominance and poor coverage against multiple serotypes (75). Dengvaxia (76) has been licensed in several countries and although the effectiveness differs between serotypes it is not clear if this is due to residual differences in antigen persistence between chimeric vaccine strains or due to the influence of prior DENV immunity present in the various populations where the vaccine was tested. More pressing, in spite of the moderate and acceptable levels of efficacy shown, some safety concerns were raised, including that children, which were likely a surrogate for flavivirus-naïve individuals since the vaccine was tested in hyperendemic regions, were more likely to require hospitalization (77). Since then, it has been surmised that an ADE-like response may be occurring in certain vaccinated individuals having breakthrough cases, which is induced by the antibodies to the vaccine (78). It is also possible that the mismatch of the virus non-structural proteins to DENV is a contributing factor to the development of breakthrough cases in vaccinated individuals (10). Supporting this, T cell responses in YFV vaccinated mice were not efficiently recalled in DENV stimulated T cells and YFV-induced CD4 T cell responses showed little cross-reactivity for DENV epitopes (14). Human cross-reactive T cell responses between YFV and DENV have been detected (14). Alternate backbones have been used for DENV vaccine strategies, including the JEV backbone, which was protective in mouse models (79) and a conserved DENV backbone, itself (80). The Takeda vaccine, for example adopted this strategy, using a DENV2 backbone with DENV1-4 structural proteins (80, 81). This strategy has the potential to provide increased recall of vaccine-induced T cell responses during natural infection with DENV viruses. Recently a clinical trial demonstrated efficacy of the Takeda vaccine in humans in a dengue-endemic region as well (82), although the long-term effects of vaccination and the persistence of protection will need to be monitored alongside the potential of any breakthrough severe disease. Importantly these vaccines illustrate how homologous and heterologous immunity to flaviviruses can change the protective capacity of a vaccine and potentially
even influence its safety. Although we are concerned with the potential of cross-reactive immunity to induce pathologies following vaccination against flaviviruses, the indications that cross-protective immunity can be induced also highlight the potential of rationale design of cross-protective vaccines that are effective against multiple flaviviruses in the future.

OUTLOOK

In spite of many recent advances toward flavivirus directed vaccines, the world wide burden of flaviviruses is actually increasing. The potential of cross-reactive immunity to influence the infection outcomes and the fact that the immune profile of individuals can change over time, being different in the months, versus years, versus decades following infection, emphasizes the need to continue studying how cross-reactive immunity works and influences infection outcomes. Compounding this is the issue of flavivirus emergence. The flavivirus genus contains diverse viruses that are present in the environment and hidden in unexplored reservoirs. The recent emergence of WNV in North America in 1999 (83), ZIKV in the South Pacific in 2013–2014 (84) and South America in 2015–16 (61) and resurgence of YFV (72), in spite of a highly effective vaccine, and growing vaccine coverage for DENV emphasizes the need to consider how cross-reactive immunity will influence infection by those flaviviruses we expect and also those that don’t have a significant burden in humans at this time.

AUTHOR CONTRIBUTIONS

AS and AR conducted literature search and analysis, and designed and wrote the manuscript.

FUNDING

This work was supported by start-up funding from Duke-NUS Medical School and grants MOE2019-T2-1-146 and NRF2016NRF-CRP001-063 to AS.

REFERENCES

1. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins Company (2001). p. 991–1041.
2. ICTV. The Online 10th Report of the International Committee on Taxonomy of Viruses. Flaviviridae, Genus Flavivirus. Available online at: https://talk.ictvonline.org/ictv-reports/ictv_online_report/positive-sense-rna-viruses/w/flaviviridae/360/genus-flavivirus.
3. Moureau G, Ninove L, Izri A, Cook S, De Lamballerie X, Charrel RN. Flavivirus RNA in phlebotomine sandflies. Vector Borne Zoonotic Dis. (2010) 10:195–7. doi: 10.1089/vbz.2008.0216
4. Norrbry E. Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. J Exp Med. (2007) 204:2779–84.
5. De Madrid AT, Porterfield JS. The Flaviviruses (group B arboviruses): a cross-neutralization study. J Gen Virol. (1974) 25:91–6.
6. Westaway EG, Brinton MA, Gaidamovich S, Horzinek MC, Igarashi A, Kaarrainen L, et al. Flaviviridae. Intervirology. (1985) 24:183–92.
7. Casals J. Viruses: the versatile parasites; the arthropod-borne group of animal viruses. Trans N Y Acad Sci. (1957) 19:219–35.
8. Casals J, Brown LV. Hemagglutination with arthropod-borne viruses. J Exp Med. (1954) 99:429–49.
9. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, et al. Antigenic relationships between Flaviviridae as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol. (1989) 70(Pt 1):37–43. doi: 10.1099/0022-1317-70-1-37.
10. St John AL, Rathore APS. Adaptive immune responses to primary and secondary dengue virus infections. Nat Rev Immunol. (2019) 19:218–30. doi: 10.1038/s41577-019-0123-x
11. Priyamvada L, Quicke KM, Hudson WH, Orlamoon N, Sewarton J, Edupuganti S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA. (2016) 113:7852–7. doi: 10.1073/pnas.1607931113
12. Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, et al. Lack of durable cross-neutralizing antibodies against Zika virus from Dengue virus infection. Emerg Infect Dis. (2017) 23:773–81. doi: 10.3201/eid2305.161630
13. Henderson BE, Cheshire PP, Kirya GB, Lube M. Immunologic studies with yellow fever and selected African group B arboviruses in rhesus and vervet monkeys. Am J Trop Med Hyg. (1970) 19:110–8.
14. Saron WAA, Rathore APS, Ting L, Ooi EE, Low J, Abraham SN, et al. Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. Sci Adv. (2018) 4:eaa4297. doi: 10.1126/sciadv.aar4297
15. Tesh RB, Travassos da Rosa AP, Guzman H, Araujo TP, Xiao SY. Immunization with heterologous Flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis. (2002) 8:245–51.
16. Makino Y, Tadano M, Saito M, Maneekarn N, Sittisombut N, Sirisatthanav V, et al. Studies on serological cross-reaction in sequential Flavivirus infections. Microbiol Immunol. (1994) 38:951–5.
17. Mansfield KL, Horton DL, Johnson N, Li L, Barrett AD, Smith DJ, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. (2011) 92(Pt 12):2821–9. doi: 10.1099/vir.0.031641-0
18. van Meer MPA, Mogling R, Klaasse J, Chandler FD, Pas SD, van der Eijk AA, et al. Re-evaluation of routine dengue virus serology in travelers in the era of Zika virus emergence. J Clin Virol. (2017) 92:25–31. doi: 10.1016/j.jcv.2017.05.001
19. Sabini AB. Research on dengue during World War II. Am J Trop Med Hyg. (1952) 1:30–50.
20. Macnamara FN, Horn DW, Porterfield JS. Yellow fever and other arthropod-borne viruses; a consideration of two serological surveys made in South Western Nigeria. Trans R Soc Trop Med Hyg. (1959) 53:202–12.
21. Blazquez AB, Escobedo-Romero E, Martin-Acebes MA, Petrovic T, Saiz JC. Limited susceptibility of mice to Usutu virus (USUV) infection and induction of Flavivirus cross-protective immunity. Virology. (2015) 482:67–71. doi: 10.1016/j.virol.2015.03.020
22. Williams DT, Daniels PW, Lunt RA, Wang LF, Newberry KM, Mackenzie JS. Experimental infections of pigs with Japanese encephalitis virus and closely related Australian Flaviviruses. Am J Trop Med Hyg. (2001) 65:579–87.
23. Salazar V, Jagger BW, Mongkolapaya J, Burgomaster KE, Dejnarritsai W, Winkler ES, et al. Dengue and Zika virus cross-reactive human monoclonal antibodies protect against spondweni virus infection and pathogenesis in mice. Cell Rep. (2019) 26:1585–97.e4. doi: 10.1016/j.celrep.2019.01.052
24. Wen J, Elong Ngono A, Regla-Nava JA, Kim K, Gorman MJ, Diamond MS, et al. Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge. Nat Commun. (2017) 8:1459. doi: 10.1038/s41467-017-01669-z
25. Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. (2017) 356:175–90. doi: 10.1126/science.aal365
26. Brown JA, Singh G, Acklin JA, Lee S, Duehr JE, Chokola AN, et al. Dengue virus immunity increases Zika virus-induced damage during pregnancy. Immunity (2019) 50:751–62.e5. doi: 10.1016/j.immuni.2019.01.005
27. Rathore APS, Saron WAA, Lim T, Jahan N, St John AL. Maternal immunity and antibodies to dengue virus promote infection and Zika virus-induced microcephaly in fetuses. Sci Adv. (2019) 5:eavz3028. doi: 10.1126/sciadv.aav3028

28. Camargos VN, Foureux G, Medeiros DC, da Silveira VT, Queiroz-Junior CD, Matsuionsu ALB, et al. In-depth characterization of congenital Zika syndrome in immunocompetent mice: antibody-dependent enhancement and an antiviral peptide therapy. EbioMedicine. (2019) 44:516–29. doi: 10.1016/j.ebiom.2019.05.014

29. Dos Santos Franco L, Gushi LT, Luiz WB, Amorim JH. Seeking Flavivirus cross-protective immunity. Front Immunol. (2019) 10:2260. doi: 10.3389/fimmu.2019.02260

30. Yachi PP, Ampudia J, Zal T, Gascoigne NR. Altered peptide ligands induce delayed CD8+T cell receptor interaction—a role for CD8 in distinguishing antigen quality. Immunity. (2006) 25:203–11.

31. Agrawal B. Heterologous immunity; role in natural and vaccine-induced resistance to infections. Front Immunol. (2019) 10:2631. doi: 10.3389/fimmu.2019.02631

32. Uren MF, Doherty PC, Allan JE. Flavivirus-specific murine L3T4+T cell clones: induction, characterization and cross-reactivity. J Gen Virol. (1987) 68(Pt 10):2655–63.

33. Hill AB, Mullbacher A, Parrish C, Coia G, Westaway EG, Blanden RV. Broad cross-reactivity with marked fine specificity in the cytotoxic T cell response to Flaviviruses. J Gen Virol. (1992) 73 (Pt 5):1115–23.

34. Spaulding AC, Kurane I, Ennis FA, Rothman AL. Analysis of murine CD8(+) T-cell clones specific for the Dengue virus NS3 protein: Flavivirus cross-reactivity and influence of infecting serotype. J Virol. (1999) 73:398–403. doi: 10.1128/JVI.73.1.398–403.1999

35. Grifoni A, Costa-Ramos P, Pham J, Sidney J, O'Rourke PH, Paul S, Peters B, et al. Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. J Virol. (2017) 91:e01469-17. doi: 10.1128/JVI.01469-17

36. Singh R, Rothman AL, Potts J, Guirakhoo F, Ennis FA, Green S. Sequential immunization with heterologous chimeric Flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses. J Infect Dis. (2010) 202:223–33. doi: 10.1086/653486

37. Grifoni A, Costa-Ramos P, Pham J, Tian Y, Rosales SL, Seumois G, et al. Cutting edge: transcriptional profiling reveals multifunctional and cytotoxic antiviral responses of Zika virus-specific CD8(+) T cells. J Immunol. (2018) 201:3487–91. doi: 10.4049/jimmunol.1801090

38. Czech P, Cantaert T, Colas C, Prot M, Casademont I, Levillayer L, et al. Germline-modified mRNA vaccine targeting immunodominant NS epitopes protects against Dengue virus infection in HLA Class I transgenic mice. Proc Natl Acad Sci USA. (2015) 112:E4256–63. doi: 10.1073/pnas.1505956112

39. Grifoni A, Aberle JH, Stasny K, Knapp B, Schreiner W, Fae I, et al. Specificities of human CD4+ T cell responses to an inactivated Flavivirus vaccine and infection: correlation with structure and epitope prediction. J Virol. (2014) 88:7828–42. doi: 10.1128/JVI.00196-14

40. Koibuchi K, Mackrodt MS, Schwaiger J, Fae I, Fischer G, Stasny K, et al. Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination. Sci Rep. (2017) 7:8907. doi: 10.1038/s41598-017-09331-w

41. Trent DW. Antigenic characterization of Flavivirus structural proteins separated by isoelectric focusing. J Virol. (1977) 22:608–18.

42. Erill WD, Chand GJ. Localization and characterization of Flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. (2004) 78:13975–86.

43. Stasny K, Kiernary M, Holzmann H, Heinz FX. Cryptic properties of a cluster of dominant Flavivirus cross-reactive antigenic sites. J Virol. (2006) 80:9557–68.

44. Fubinianah S, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, et al. A highly potently human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. (2015) 6:6341. doi: 10.1038/ncomms7341

45. Rey FA, Stasny K, Vaney MC, Dellarole M, Heinz FX. The bright and the dark side of human antibody responses to Flaviviruses: lessons for vaccine design. EMBO Rep. (2018) 19:206–24. doi: 10.15252/embr.201745302

46. Collins MH, Tu HA, Gimblet-Ochieng C, Liou GA, Jadi RS, Metz SW, et al. Human antibody response to Zika targets type-specific quaternary structure epitopes. JCI Insight. (2019) 4:e124588. doi: 10.1172/jci.insight.124588

47. Metz SW, Thomas A, Brackbill A, Forsberg J, Miley MJ, Lopez CA, et al. Oligomeric state of the Zika V protein defines protective immune responses. Nat Commun. (2019) 10:4606. doi: 10.1038/s41467-019-12677-6

48. Barba-Spaeth G, Dejirattisai W, Rouvinski A, Vaney MC, Medicts I, Sharma A, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. (2016) 536:46–53. doi: 10.1038/nature18938

49. Fernandes E, Dejirattisai W, Caao B, Scheaffer SM, Supasa P, Wongwiwat W, et al. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. J Virol. (2017) 91:12861–7. doi: 10.1128/JVI.02849-17

50. Katsnelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. (2017) 358:929–32. doi: 10.1126/science.aan6836

51. Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, Yang HO, et al. A broadly Flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One. (2011) 6:e16059. doi: 10.1371/journal.pone.0016059

52. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. (2007) 1:135–45.

53. Tajima S, Takasaki T, Matsuono S, Nakayama M, Kurane I. Genetic characterization of yokose virus, a Flavivirus isolated from the bat in Japan. Virology. (2005) 332:38–44. doi: 10.1016/j.virol.2004.06.052

54. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. (2013) 496:504–7. doi: 10.1038/nature12060

55. Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev. (2016) 29:487–524. doi: 10.1128/CMR.00072-15

56. Syenina A, Jagaraj CJ, Aman SA, Sridharan A, St John AL. Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fc gamma receptors. Elife. (2015) 4:e05291. doi: 10.7554/eLife.05291

57. St John AL. Influence of mast cells on dengue protective immunity and immune pathology. PLoS Pathog. (2013) 9:e1003783. doi: 10.1371/journal.ppat.1003783

58. Kurane I, Hebbelewaite D, Brandt WE, Ennis FA. Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Virol. (1984) 57:223–30.

59. Dejirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus serum-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol. (2016) 17:1102–8. doi: 10.1038/nimm.2015.315

60. Chan KR, Wang X, Saron WAA, Gan ES, Tan HC, Mok DZL, et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat Microbiol. (2016) 1:1664. doi: 10.1038/nmicrobiol.2016.164
67. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus Flavivirus. J Virol. (1998) 72:73–83. doi: 10.1128/jvi.72.1.73-83. 1998
68. Robbiani DE, Olsen PC, Costa F, Wang Q, Oliveira TY, Nery N Jr., et al. Risk of Zika microcephaly correlates with features of maternal antibodies. J Exp Med. (2019) 216:2302–15. doi: 10.1084/jem.20191061
69. Rodriguez-Barraquer I, Costa F, Nascimento EJM, Nery NJ, Castanha PMS, Sacramento GA, et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science. (2019) 363:607–10. doi: 10.1126/science.aav6618
70. Bradi V, Malafa S, von Braun A, Jarmer J, Tsouchnikas G, Medits I, et al. Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination. NPJ Vaccines. (2019) 5:38. doi: 10.1038/s41541-019-0133-5
71. Grosbelaar AA, Weyer J, Moolla N, Jansen van Vuren P, Moises F, Paweska JT. Resurgence of yellow fever in Angola, 2015-2016. Emerg Infect Dis. (2016) 22:1854–5.
72. Chen LH, Kozarsky PE, Visser LG. What's old is new again: the re-emergence of yellow fever in Brazil and vaccine shortages. Clin Infect Dis. (2019) 68:1761–2. doi: 10.1093/cid/ciy777
73. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. (2009) 9:741–7. doi: 10.1038/nri2629
74. Guy B, Guirakhoo F, Barbau V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. (2010) 28:632–49. doi: 10.1016/j.vaccine.2009.09.098
75. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. (2002) 66:264–72.
76. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. (2014) 384:1358–65. doi: 10.1016/S0140-6736(14)61060-6
77. Arredondo-Garcia JL, Hadinegoro SR, Reyes H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, et al. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect. (2018) 24:755–63. doi: 10.1016/j.cmi.2018.01.018
78. Gubler DJ, Halstead SB. Is Dengvaxia a useful vaccine for dengue endemic areas? BMJ. (2019) 367:j35710. doi: 10.1136/bmj.j35710
79. Yang H, Li Z, Lin H, Wang W, Yang J, Liu L, et al. A novel dengue virus serotype 1 vaccine candidate based on Japanese encephalitis virus vaccine strain SA14-14-2 as the backbone. Arch Virol. (2016) 161:1517–26. doi: 10.1007/s00705-016-2817-8
80. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. (2011) 29:7251–60. doi: 10.1016/j.vaccine.2011.07.020
81. Saez-Llorens X, Tricou V, Yu D, Rivera L, Jimeno J, Villarreal AC, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis. (2018) 18:162–70. doi: 10.1016/S1473-3099(17)30632-1
82. Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. Efficacy of a tetravalent Dengue vaccine in healthy children and adolescents. N Engl J Med. (2019) 381:2009–19. doi: 10.1056/NEJMoa1903869
83. Roehrig JT, Layton M, Smith P, Campbell GL, Nasci R, Lanciotti RS. The emergence of West Nile virus in North America: ecology, epidemiology, and surveillance. Curr Top Microbiol Immunol. (2002) 267:223–40.
84. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, et al. Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis. (2014) 20:1085–6.
85. Fontenille D, Traore-Lamizana M, Trouillet J, Leclerc A, Mondo M, Ba Y, et al. First isolations of arboviruses from phlebotomine sand flies in West Africa. Am J Trop Med Hyg. (1994) 50:570–4.
86. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. (2016) 33:1870–4. doi: 10.1093/molbev/msw054
87. Jones DT, Taylor WR, Thornton JM. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci. (1992) 8:275–82.
88. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. (1985) 39:783–91. doi: 10.1111/j.1558-5646.1985.tb00420.x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Rathore and St. John. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.